annual cost of prep therapy for hiv
There are many methods besides condoms that people are using to reduce their HIV risk. Some people serosort by partnering with people who have the same HIV status, reduce the number of people they have sex with, use female condoms, have sex with HIV-positive partner(s) with undetectable viral load(s), and/or use PrEP. Some methods are more effective than others depending on multiple factors. The costs assumed for PrEP range from $525 to $830 per person per year of which the majority of the cost is for the drug – $420 for tenofovir and $600 for tenofovir/FTC (Truvada). The cost per disability-adjusted life-year with HIV (HIV DALY) averted. How this cost measured up against two different definitions of cost-effectiveness. The effect of behaviour change, measured as a change in condom use in PrEP users from a 30% increase to a 100% decrease. Currently, the only drug which any health organization recommends for PrEP is Truvada, which is the brand name of the Gilead Sciences drug combination of tenofovir/emtricitabine. PrEP is not the right fit for everyone but may be useful for men, women, and transwomen who are at risk for HIV infection through sex and injecting drug use and okay with the idea of taking a daily pill to prevent HIV. In this scenario, it would cost about $500 per DALY. At 20% coverage, targeted PrEP would cost $800 per HIV DALY averted. At both levels of coverage, non-targeted PrEP would cost about $1400 per DALY. This picture changes if the costs of ART for people who would otherwise be infected is also included. In 2008, the iPrEx study demonstrated 42% reduction of HIV infection among men who have sex with men, and subsequent analysis of the data has suggested that 99% protection is achievable if the drugs are taken every day. PrEP approaches with agents besides oral Truvada are currently in clinical trials not listed here. The terms pre-exposure prophylaxis and PrEP most commonly refer to an HIV-prevention strategy where antiretrovirals are used to protect HIV-negative people from HIV infection. The HIV antiviral Truvada was approved by the FDA for PrEP on 16 July 2012. No. If you have been exposed to HIV, PrEP is not the best option for you because it is meant to reduce your risk before exposure. If you are reading this within 72 hours after exposure, consider starting PEP (short for post-exposure prophylaxis), a month-long course of drugs that can reduce the likelihood of infection. PrEP, an acronym from Pre-Exposure Prophylaxis, is the use of prescription drugs by people who do not have HIV/AIDS as a strategy for the prevention of HIV/AIDS.
Targeted PrEP would cost $800 per HIV and non-targeted PrEP would cost about $1400.